By Topic
Is 4DMedical (ASX: 4DX) the Next High-Growth MedTech Breakout or a Funding Risk?
4DMedical Limited is an Australian medtech company developing lung imaging software that turns standard scans into functional insights. It has strong growth potential through scalable products like CT:VQ, but remains speculative due to ongoing cash burn, reliance on adoption, and funding risk.
Invictus Energy (ASX: IVZ): Billion-Barrel Potential or Bust?
Invictus Energy is an early-stage oil and gas explorer in Zimbabwe with large but unproven resource potential. With no revenue and heavy funding needs, the stock offers significant upside if discoveries succeed, but remains a high-risk, news-driven investment.
Encounter Resources’ (ASX: ENR) share price is showing signs of a reversal
Encounter Resources (ASX: ENR) is an Australian mineral explorer targeting copper and critical minerals. Backed by solid funding and major partnerships, its share price exhibits bullish reversal signs, though future growth relies heavily on successful high-grade exploration discoveries.
Is Dateline Resources (ASX: DTR) Positioning for Stabilisation After Extended Weakness?
Dateline Resources (ASX: DTR) is advancing its California-based gold and rare earth projects while navigating funding, dilution, and execution risks. Technically, the stock is testing major long-term support near 0.16, with RSI conditions suggesting a possible stabilisation phase if buying interest returns.
Hawk Resources (ASX: HWK): Is the Volume Surge Pointing to a Fresh Breakout Attempt?
Hawk Resources is an early-stage explorer targeting high-grade copper-gold in Utah and lithium in Brazil, with emerging exposure to rare earths. Recent trading was driven by its Olympus scandium deal, a A$5.87A$5.87 million raising, and renewed momentum at Cactus.
Nyrada (ASX: NYR) Shares Are Suddenly Back on Traders’ Radar After Sharp Price Swing
Nyrada (ASX: NYR) shares have seen sharp volatility as traders react to its Xolatryp clinical progress and Phase IIa plans. Despite strong preclinical results and early trial safety data, the stock remains speculative, driven by momentum trading, retail interest, and upcoming biotech milestones.
...